Belimumab safety in adult and paediatric Chinese patients with systemic lupus erythematosus: A Phase 4, multicentre, observational study
Belimumab was generally well tolerated in adult and paediatric patients with SLE in this real-world setting in China, with no new safety signals identified. Future assessment of long-term belimumab safety in China beyond 24 weeks will extend this current body of evidence.
Authors
- Jingwen Hu (ORCID: https://orcid.org/0000-0001-6477-0360)
- Shanzhi He
- Zhizhong Ye
- Shuhong Chi (ORCID: https://orcid.org/0000-0003-1141-7605)
- Avery Tung (ORCID: https://orcid.org/0000-0003-2670-0833)
- Yifan He (ORCID: https://orcid.org/0000-0002-8312-8071)
- Jing Yang (ORCID: https://orcid.org/0000-0001-6441-709X)
- Lin Tang (ORCID: https://orcid.org/0000-0001-6996-7955)
- Qinghong Yu (ORCID: https://orcid.org/0000-0003-3507-3667)
- Weibo Wang (ORCID: https://orcid.org/0000-0002-4420-385X)
- Min Yang (ORCID: https://orcid.org/0000-0002-1024-8400)
- Songlou Yin (ORCID: https://orcid.org/0000-0001-5341-2381)
- Xuefeng Zhao (ORCID: https://orcid.org/0000-0002-4049-0396)
- Chuanmei Xie
- Zhuoli Zhang
Institutions
- Xuzhou Medical College (CN)
- Dalian Medical University (CN)
- Peking University (CN)
- Mianyang Central Hospital (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Nanfang Hospital (CN)
- Zhongshan People's Hospital (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
- Zhujiang Hospital (CN)
- Ningxia Medical University (CN)
- Peking University First Hospital (CN)
- GlaxoSmithKline (China) (CN)
- Ningxia Medical University General Hospital (CN)
- Southern Medical University (CN)
- China Development Bank (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Lupus
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1177/09612033241299175
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.47